ALN-PNP + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Genetic Risk Factor
Trial Timeline
May 21, 2024 → Jul 7, 2025
NCT ID
NCT06024408About ALN-PNP + Placebo
ALN-PNP + Placebo is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Nonalcoholic Fatty Liver Disease (NAFLD). The current trial status is completed. This product is registered under clinical trial identifier NCT06024408. Target conditions include Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Genetic Risk Factor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06024408 | Phase 1 | Completed |
Competing Products
20 competing products in Nonalcoholic Fatty Liver Disease (NAFLD)